Xvivo Perfusion AB (publ), a medical technology company, develops solutions and systems for selecting usable organs and maintaining them in optimal condition pending transplantation.
Flawless balance sheet with high growth potential.
Share Price & News
How has Xvivo Perfusion's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: XVIVO's share price has been volatile over the past 3 months.
7 Day Return
SE Medical Equipment
1 Year Return
SE Medical Equipment
Return vs Industry: XVIVO underperformed the Swedish Medical Equipment industry which returned 12.4% over the past year.
Return vs Market: XVIVO underperformed the Swedish Market which returned -11.6% over the past year.
Price Volatility Vs. Market
How volatile is Xvivo Perfusion's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StThese Analysts Just Made A Huge Downgrade To Their Xvivo Perfusion AB (publ) (STO:XVIVO) EPS Forecasts
1 month ago | Simply Wall StDid Business Growth Power Xvivo Perfusion's (STO:XVIVO) Share Price Gain of 298%?
2 months ago | Simply Wall StEarnings Miss: Xvivo Perfusion AB (publ) Missed EPS By 60% And Analysts Are Revising Their Forecasts
Is Xvivo Perfusion undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: XVIVO (SEK104.8) is trading below our estimate of fair value (SEK157.42)
Significantly Below Fair Value: XVIVO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: XVIVO is poor value based on its PE Ratio (562.7x) compared to the Medical Equipment industry average (49.5x).
PE vs Market: XVIVO is poor value based on its PE Ratio (562.7x) compared to the Swedish market (14.8x).
Price to Earnings Growth Ratio
PEG Ratio: XVIVO is poor value based on its PEG Ratio (7.8x)
Price to Book Ratio
PB vs Industry: XVIVO is overvalued based on its PB Ratio (4.8x) compared to the SE Medical Equipment industry average (3.6x).
How is Xvivo Perfusion forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XVIVO's forecast earnings growth (72.2% per year) is above the savings rate (-0.4%).
Earnings vs Market: XVIVO's earnings (72.2% per year) are forecast to grow faster than the Swedish market (8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: XVIVO's revenue (28.1% per year) is forecast to grow faster than the Swedish market (4.1% per year).
High Growth Revenue: XVIVO's revenue (28.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: XVIVO's Return on Equity is forecast to be low in 3 years time (14.7%).
How has Xvivo Perfusion performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XVIVO has high quality earnings.
Growing Profit Margin: XVIVO's current net profit margins (2.2%) are lower than last year (6.8%).
Past Earnings Growth Analysis
Earnings Trend: XVIVO's earnings have grown significantly by 22.5% per year over the past 5 years.
Accelerating Growth: XVIVO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: XVIVO had negative earnings growth (-61.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (12.6%).
Return on Equity
High ROE: XVIVO's Return on Equity (0.9%) is considered low.
How is Xvivo Perfusion's financial position?
Financial Position Analysis
Short Term Liabilities: XVIVO's short term assets (SEK259.9M) exceed its short term liabilities (SEK52.6M).
Long Term Liabilities: XVIVO's short term assets (SEK259.9M) exceed its long term liabilities (SEK4.4M).
Debt to Equity History and Analysis
Debt Level: XVIVO is debt free.
Reducing Debt: XVIVO had no debt 5 years ago.
Debt Coverage: XVIVO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: XVIVO has no debt, therefore coverage of interest payments is not a concern.
Inventory Level: XVIVO has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if XVIVO's debt is covered by short term assets.
What is Xvivo Perfusion's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XVIVO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate XVIVO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XVIVO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XVIVO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of XVIVO's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Magnus Nilsson (63yo)
Dr. Magnus Nilsson, Ph.D., has been the Chief Executive Officer of Xvivo Perfusion AB since 2011. Dr. Nilsson served as the Chief Executive Officer and President of Vitrolife AB (publ) from January 2003 to ...
CEO Compensation Analysis
Compensation vs Market: Magnus's total compensation ($USD907.14K) is above average for companies of similar size in the Swedish market ($USD533.60K).
Compensation vs Earnings: Magnus's compensation has been consistent with company performance over the past year.
|MD & CEO||9.25yrs||kr9.17m||0.75% SEK20.0m|
|CFO, Deputy CEO||8.25yrs||no data||0.20% SEK5.4m|
|Operations Director||1.5yrs||no data||no data|
|no data||no data||no data|
|Marketing and Sales Director of EMEA & Pacific||4.33yrs||no data||0.0094% SEK250.0k|
Experienced Management: XVIVO's management team is seasoned and experienced (6.3 years average tenure).
|Chairman of the Board||2yrs||kr205.00k||0.0075% SEK200.0k|
|Director||1yr||no data||no data|
Experienced Board: XVIVO's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Xvivo Perfusion AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Xvivo Perfusion AB (publ)
- Ticker: XVIVO
- Exchange: OM
- Founded: 1998
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr2.660b
- Shares outstanding: 26.60m
- Website: https://www.xvivoperfusion.com
Number of Employees
- Xvivo Perfusion AB (publ)
- Box 53015
- Västra Götaland County
- 400 14
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|XVIVO||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||Oct 2012|
|XVIP.F||OTCPK (Pink Sheets LLC)||Yes||Share Capital||US||USD||Oct 2012|
|0RKL||LSE (London Stock Exchange)||Yes||Share Capital||GB||SEK||Oct 2012|
|XVIVOS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Share Capital||GB||SEK||Oct 2012|
Xvivo Perfusion AB (publ), a medical technology company, develops solutions and systems for selecting usable organs and maintaining them in optimal condition pending transplantation. The company offers XVIVO Perfusion System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex-vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex, a buffered extracellular colloid-based electrolyte preservation solution; Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. Xvivo Perfusion AB (publ) was founded in 1998 and is headquartered in Gothenburg, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/04 00:53|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.